- Home
- CGNT vs ARCT Comparison
CGNT vs ARCT Comparison
Compare CGNT & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- ARCT
- Stock Information
- Founded
- CGNT 2020
- ARCT 2013
- Country
- CGNT Israel
- ARCT United States
- Employees
- CGNT N/A
- ARCT N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- ARCT Health Care
- Exchange
- CGNT Nasdaq
- ARCT Nasdaq
- Market Cap
- CGNT 669.2M
- ARCT 298.3M
- IPO Year
- CGNT N/A
- ARCT N/A
- Fundamental
- Price
- CGNT $9.30
- ARCT $13.19
- Analyst Decision
- CGNT Hold
- ARCT Strong Buy
- Analyst Count
- CGNT 1
- ARCT 8
- Target Price
- CGNT N/A
- ARCT $52.33
- AVG Volume (30 Days)
- CGNT 455.6K
- ARCT 497.0K
- Earning Date
- CGNT 06-11-2025
- ARCT 08-04-2025
- Dividend Yield
- CGNT N/A
- ARCT N/A
- EPS Growth
- CGNT N/A
- ARCT N/A
- EPS
- CGNT N/A
- ARCT N/A
- Revenue
- CGNT $363,466,000.00
- ARCT $143,680,000.00
- Revenue This Year
- CGNT $14.94
- ARCT N/A
- Revenue Next Year
- CGNT $9.57
- ARCT $34.79
- P/E Ratio
- CGNT N/A
- ARCT N/A
- Revenue Growth
- CGNT 12.58
- ARCT 15.38
- 52 Week Low
- CGNT $6.21
- ARCT $8.04
- 52 Week High
- CGNT $11.66
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- CGNT 42.17
- ARCT 66.19
- Support Level
- CGNT $8.73
- ARCT $12.03
- Resistance Level
- CGNT $9.40
- ARCT $14.75
- Average True Range (ATR)
- CGNT 0.42
- ARCT 0.79
- MACD
- CGNT -0.12
- ARCT 0.20
- Stochastic Oscillator
- CGNT 21.92
- ARCT 89.96
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.